A confirmatory basket design considering non-inferiority and superiority testing

References

• Bayer HealthCare Pharmaceuticals. (2019). Vitrakvi prescribing information. http://labeling.bayerhealthcare.com/html/products/pi/vitrakvi_PI.pdf.
   Google Scholar
• Beckman, R. A., Z. Antonijevic, R. Kalamegham, and C. Chen. 2016. Adaptive design for a confirmatory basket trial in multiple tumor types based on a putative predictive biomarker. Clinical Pharmacology and Therapeutics 100 (6):617–625. doi:10.1002/cpt.446.
   PubMed Web of Science ®Google Scholar
• Berry, S. M., K. R. Broglio, S. Groshen, and D. A. Berry. 2013. Bayesian hierarchical modeling of patient subpopulations: Efficient designs of phase II oncology trials. Clinical Trials 10 (5):720–734. doi:10.1177/1740774513497539.
   PubMed Web of Science ®Google Scholar
• Chen, C., X. Li, S. Yuan, Z. Antonijevic, R. Kalamegham, and R. A. Beckman. 2016. Statistical design and considerations of a phase 3 basket trial for simultaneous investigation of multiple tumor types in one study. Statistics in Biopharmaceutical Research 8 (3):248–257. doi:10.1080/19466315.2016.1193044.
   Web of Science ®Google Scholar
• Chu, Y., and Y. Yuan. 2018a. BLAST: Bayesian latent subgroup design for basket trials accounting for patient heterogeneity. Journal of the Royal Statistical Society: Series C (Applied Statistics) 67 (3):723–740. doi:10.1111/rssc.12255.
   Web of Science ®Google Scholar
• Chu, Y., and Y. A. Yuan. 2018b. Bayesian basket trial design using a calibrated Bayesian hierarchical model. Clinical Trials 15 (2):149–158. doi:10.1177/1740774518755122.
   PubMed Web of Science ®Google Scholar
• Cunanan, K. M., A. Iasonos, R. Shen, C. B. Begg, and M. Gönen. 2017. An efficient basket trial design. Statistics in Medicine 36:1568–1579. doi:10.1002/sim.7227.
   PubMed Web of Science ®Google Scholar
• EMA (2005). Guideline on the choice of the non-inferiority margin. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-choice-non-inferiority-margin_en.pdf. Accessed Oct 20, 2022
   Google Scholar
• FDA (2014) Statistical review of CERDEGLA; https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205494Orig1s000StatR.pdf, accessed Oct 4, 2022
   Google Scholar
• FDA (2016). Non-Inferiority clinical trials to establish effectiveness. accessed Oct 20, 2022 https://www.fda.gov/media/78504/download
   Google Scholar
• FDA. 2018a. Developing targeted therapies in low-frequency molecular subsets of a disease. Guidance for Industry. https://www.fda.gov/media/117173/download
   Google Scholar
• FDA. 2018b. Master protocols: Efficient clinical trial design strategies to expedite development of oncology drugs and biologics. Draft guidance for Industry. https://www.fda.gov/media/120721/download
   Google Scholar
• Felthouse, D. H. 2008. Focus on lowest net cost drug reduces costs for patients, plan sponsors. American Health & Drug Benefits 1 (9):10–11.
   PubMedGoogle Scholar
• Heinrich, M. C., H. Joensuu, G. D. Demetri, C. L. Corless, J. Apperley, J. A. Fletcher, D. Soulieres, S. Dirnhofer, A. Harlow, A. Town, et al. 2008. Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases. Clinical Cancer Research 14(9):2717–2725. doi:10.1158/1078-0432.CCR-07-4575.
   PubMed Web of Science ®Google Scholar
• He, L., Y. Ren, H. Chen, D. Guinn, D. Parashar, C. Chen, S. S. Yuan, V. Korostyshevskiy, and R. A. Beckman. 2022. Efficiency of a randomized confirmatory basket trial design constrained to control the false positive rate by indication. Statistical Methods in Medical Research 31 (7):1207–1223. doi:10.1177/09622802221091901.
   PubMed Web of Science ®Google Scholar
• Hyman, D. M., I. Puzanov, V. Subbiah, J. E. Faris, I. Chau, J. Y. Blay, J. Wolf, N. S. Raje, E. L. Diamond, A. Hollebecque, et al. 2015. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. The New England Journal of Medicine 373(8):726–736. doi:10.1056/NEJMoa1502309.
   PubMed Web of Science ®Google Scholar
• Jing, N., F. Liu, C. Wu, H. Zhou, and C. Chen. 2022. An optimal two-stage exploratory basket trial design with aggregated futility analysis. Contemporary Clinical Trials 116:106741. doi:10.1016/j.cct.2022.106741.
   PubMed Web of Science ®Google Scholar
• Lengliné, E., J. Peron, A. Vanier, F. Gueyffier, S. Kouzan, P. Dufour, B. Guillot, H. Blondon, M. Clanet, P. Cochat, et al. 2021. Basket clinical trial design for targeted therapies for cancer: A French National Authority for Health statement for health technology assessment. The Lancet Oncology 22 (10):e430–434. doi:10.1016/S1470-2045(21)00337-5.
   PubMed Web of Science ®Google Scholar
• McArthur, G. A., G. D. Demetri, A. van Oosterom, M. C. Heinrich, M. Debiec-Rychter, C. L. Corless, Z. Nikolova, S. Dimitrijevic, and J. A. Fletcher. 2005. Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 23 (4):866–873. doi:10.1200/JCO.2005.07.088. PMID: 15681532.
   PubMed Web of Science ®Google Scholar
• Novo nordisk a/s, efficacy and safety of continuous subcutaneous insulin infusion of faster-acting insulin aspart compared to novorapid® in adults with type 1 diabetes (onset® 5), ClinicalTrials.Gov identifier: NCT02825251. Updated Nov 21, 2019a. Accessed Nov 21, 2022.
   Google Scholar
• Novo nordisk a/s, efficacy and safety of faster-acting insulin aspart compared to novorapid® both in combination with insulin degludec in adults with type 1 diabetes (onset®8), ClinicalTrials.Gov identifier: NCT02500706. Updated June 12, 2019b.Accessed Oct07, 2022.
   Google Scholar
• Novo nordisk a/s, efficacy and safety of faster-acting insulin aspart compared to novorapid® both in combination with insulin degludec in children and adolescents with type 1 diabetes (onset®7), ClinicalTrials.Gov identifier: NCT02670915. Updated June 5, 2019c. Accessed Oct 07, 2022.
   Google Scholar
• Novo nordisk a/s, efficacy and safety of fiasp compared to insulin aspart both in combination with insulin detemir in adults with type 1 diabetes (onset® 1), ClinicalTrials.Gov identifier: NCT01831765. Updated June 12, 2019d. Accessed Oct 07, 2022.
   Google Scholar
• Plimack, E. R., J. Bellmunt, S. Gupta, R. Berger, L. Q. Chow, J. Juco, J. Lunceford, S. Saraf, R.F. Perini, P. H. O'Donnell, et al. 2017. Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): A non-randomised, open-label, phase 1b study. The Lancet Oncology 18 (2):212–220. doi:10.1016/S1470-2045(17)30007-4
   PubMed Web of Science ®Google Scholar
• Psioda, M. A., J. Xu, Q. Jiang, C. Ke, Z. Yang, and J. G. Ibrahim. 2021. Bayesian adaptive basket trial design using model averaging. Biostatistics 22 (1):19–34. doi:10.1093/biostatistics/kxz014.
   PubMed Web of Science ®Google Scholar
• Rothman, M., N. Li, G. Chen, et al. 2003. Design and analysis of non-inferiority mortality trials in oncology. Statistics in Medicine 22:239–264.
   PubMed Web of Science ®Google Scholar
• Rothman, M., and H. Tsou. 2003. On non-inferiority analysis based on delta-method confidence intervals. Journal of Biopharmaceutical Statistics 13:565–583.
   PubMedGoogle Scholar
• Sanofi, C. E. R. D. E. L. G. A. https://products.sanofi.us/cerdelga/cerdelga.html accessed Oct 4, 2022.
   Google Scholar
• Schumi, J., and J. Wittes. 2011. Through the looking glass: Understanding non-inferiority. Trials 12:106.
   PubMed Web of Science ®Google Scholar
• Simon, R., S. Geyer, J. Subramanian, et al. 2016. The Bayesian basket design for genomic-variant driven phase II trials. Seminars in Oncology 43:13–18.
   PubMed Web of Science ®Google Scholar
• Snappin, S., and Q. Jiang. 2008a. Controlling the type 1 error rate in non-inferiority trials. Statistics in Medicine 27:371–381.
   PubMed Web of Science ®Google Scholar
• Snappin, S., and Q. Jiang. 2008b. Preservation of effect and the regulatory approval of new treatments on the basis of non-inferiority trials. Statistics in Medicine 27:382–391.
   PubMed Web of Science ®Google Scholar
• Takeda, K., S. Liu, and A. Rong. 2022. Constrained hierarchical Bayesian model for latent subgroups in basket trials with two classifiers. Statistics in Medicine 41 (2):298–309.
   PubMed Web of Science ®Google Scholar
• Woodcock, J., and L. M. LaVange. 2017. Master protocols to study multiple therapies, multiple diseases, or both. The New England Journal of Medicine 377 (1):62–70.
   PubMed Web of Science ®Google Scholar
• Wu, X., C. Wu, F. Liu, H. Zhou, and C. Chen. 2021. A generalized framework of optimal two-stage designs for exploratory basket trials. Statistics in Biopharmaceutical Research 13 (3):286–294.
   Web of Science ®Google Scholar
• Yin, G., Z. Yang, M. Odani, and S. Fukimbara. 2021. Bayesian hierarchical modeling and biomarker cutoff identification in basket trials. Statistics in Biopharmaceutical Research 13 (2):248–258.
   Web of Science ®Google Scholar
• Zhou, H., F. Liu, C. Wu, E. H. Rubin, V. L. Giranda, and C. Chen. 2019. Optimal two-stage designs for exploratory basket trials. Contemporary Clinical Trials 85:105807.
   PubMed Web of Science ®Google Scholar